Point72 Asset Management L.P. Sells 89,785 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Point72 Asset Management L.P. decreased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 91.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,461 shares of the company's stock after selling 89,785 shares during the quarter. Point72 Asset Management L.P.'s holdings in Cellebrite DI were worth $186,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Barclays PLC lifted its position in shares of Cellebrite DI by 29.1% in the third quarter. Barclays PLC now owns 263,657 shares of the company's stock valued at $4,439,000 after buying an additional 59,395 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Cellebrite DI by 2,244.2% during the 4th quarter. SG Americas Securities LLC now owns 209,529 shares of the company's stock worth $4,616,000 after purchasing an additional 200,591 shares during the last quarter. Janney Montgomery Scott LLC increased its position in Cellebrite DI by 30.0% during the 4th quarter. Janney Montgomery Scott LLC now owns 66,487 shares of the company's stock worth $1,465,000 after buying an additional 15,332 shares during the period. Juncture Wealth Strategies LLC boosted its holdings in Cellebrite DI by 0.8% in the 4th quarter. Juncture Wealth Strategies LLC now owns 60,003 shares of the company's stock valued at $1,322,000 after purchasing an additional 505 shares during the period. Finally, Blue Trust Inc. acquired a new stake in Cellebrite DI during the fourth quarter worth approximately $466,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Trading Down 1.2%

Shares of CLBT traded down $0.20 during trading hours on Friday, reaching $16.58. 325,141 shares of the stock traded hands, compared to its average volume of 1,455,940. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The stock has a fifty day simple moving average of $18.73 and a 200 day simple moving average of $20.13. The company has a market cap of $3.97 billion, a price-to-earnings ratio of -11.95, a PEG ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. The company had revenue of $107.55 million for the quarter, compared to the consensus estimate of $109.36 million. During the same period in the previous year, the firm earned $0.08 EPS. The firm's quarterly revenue was up 20.0% on a year-over-year basis. Analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. dropped their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Lake Street Capital raised their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Finally, Needham & Company LLC lowered their target price on Cellebrite DI from $28.00 to $24.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI presently has a consensus rating of "Buy" and a consensus price target of $22.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.